Reviewing Tectonic Therapeutic (TECX) and Its Rivals

Tectonic Therapeutic (NASDAQ:TECX) is one of 282 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare Tectonic Therapeutic to similar businesses based on the strength of its earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and dividends.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Tectonic Therapeutic and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	0	0	3	1	3.25
Tectonic Therapeutic Competitors	1533	4512	11756	211	2.59

Tectonic Therapeutic currently has a consensus target price of $62.50, indicating a potential upside of 267.22%. As a group, “Biological products, except diagnostic” companies have a potential upside of 75.11%. Given Tectonic Therapeutic’s stronger consensus rating and higher probable upside, analysts clearly believe Tectonic Therapeutic is more favorable than its peers.

Insider and Institutional Ownership

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 9.2% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 16.4% of shares of all “Biological products, except diagnostic” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Tectonic Therapeutic and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Tectonic Therapeutic	N/A	$12.16 million	24.67
Tectonic Therapeutic Competitors	$546.42 million	-$33.02 million	-24.46

Tectonic Therapeutic’s peers have higher revenue, but lower earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Tectonic Therapeutic has a beta of 2.63, meaning that its share price is 163% more volatile than the S&P 500. Comparatively, Tectonic Therapeutic’s peers have a beta of 1.05, meaning that their average share price is 5% more volatile than the S&P 500.

Profitability

This table compares Tectonic Therapeutic and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-50.52%	-47.13%
Tectonic Therapeutic Competitors	-2,867.99%	-206.87%	-45.78%

Summary

Tectonic Therapeutic beats its peers on 10 of the 13 factors compared.

About Tectonic Therapeutic

Avrobio, Inc. is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc. is based in MA, United States.